M. Chartier

432 total citations
44 papers, 334 citations indexed

About

M. Chartier is a scholar working on Rheumatology, Genetics and Pathology and Forensic Medicine. According to data from OpenAlex, M. Chartier has authored 44 papers receiving a total of 334 indexed citations (citations by other indexed papers that have themselves been cited), including 25 papers in Rheumatology, 20 papers in Genetics and 18 papers in Pathology and Forensic Medicine. Recurrent topics in M. Chartier's work include Rheumatoid Arthritis Research and Therapies (19 papers), Chronic Lymphocytic Leukemia Research (18 papers) and Lymphoma Diagnosis and Treatment (16 papers). M. Chartier is often cited by papers focused on Rheumatoid Arthritis Research and Therapies (19 papers), Chronic Lymphocytic Leukemia Research (18 papers) and Lymphoma Diagnosis and Treatment (16 papers). M. Chartier collaborates with scholars based in France, Germany and Italy. M. Chartier's co-authors include C. Rauch, Rieke Alten, H. Nüßlein, Manuela Le Bars, Mauro Galeazzi, Coralie Poncet, Hanns‐Martin Lorenz, Xavier Mariette, Michael T. Nurmohamed and W. Bensen and has published in prestigious journals such as Annals of the Rheumatic Diseases, BioMed Research International and Lara D. Veeken.

In The Last Decade

M. Chartier

37 papers receiving 318 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
M. Chartier France	11	264	85	80	78	76	44	334
T. Ziglioli Italy	6	165 0.6×	44 0.5×	21 0.3×	51 0.7×	34 0.4×	7	262
Eric Amante Australia	5	361 1.4×	113 1.3×	65 0.8×	193 2.5×	45 0.6×	7	417
Benjamin Empson United Kingdom	2	204 0.8×	23 0.3×	35 0.4×	21 0.3×	61 0.8×	2	267
H-P Tony Germany	9	242 0.9×	56 0.7×	43 0.5×	69 0.9×	46 0.6×	23	381
Zhiyu Ge United States	4	465 1.8×	134 1.6×	111 1.4×	226 2.9×	96 1.3×	5	582
Sau Mei Tse China	10	314 1.2×	17 0.2×	39 0.5×	57 0.7×	54 0.7×	18	372
María Kourilovitch Ecuador	7	159 0.6×	15 0.2×	15 0.2×	60 0.8×	29 0.4×	8	267
Carolina Muñoz‐Grajales Colombia	9	92 0.3×	47 0.6×	48 0.6×	55 0.7×	16 0.2×	44	249
Griselda Galindo-Rodrı́guez Mexico	11	183 0.7×	31 0.4×	42 0.5×	55 0.7×	24 0.3×	14	326
Chamaida Plasencia‐Rodríguez Spain	13	346 1.3×	30 0.4×	24 0.3×	132 1.7×	50 0.7×	50	458

Countries citing papers authored by M. Chartier

Since Specialization

Citations

This map shows the geographic impact of M. Chartier's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by M. Chartier with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites M. Chartier more than expected).

Fields of papers citing papers by M. Chartier

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by M. Chartier. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by M. Chartier. The network helps show where M. Chartier may publish in the future.

Co-authorship network of co-authors of M. Chartier

This figure shows the co-authorship network connecting the top 25 collaborators of M. Chartier. A scholar is included among the top collaborators of M. Chartier based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with M. Chartier. M. Chartier is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Chartier, M., et al.. (2025). Treatment sequences of biological and targeted synthetic disease-modifying antirheumatic drugs for rheumatoid arthritis: A nationwide population-based study in France. Joint Bone Spine. 93(3). 106023–106023.

Anglicheau, Dany, Antoine Dürrbach, Isabelle Bardoulat, et al.. (2025). Immunosuppressive treatment patterns in kidney transplant recipients in France: an insurance claims database study (OISTER) over a 12 year period. Journal of Nephrology. 38(4). 1229–1237.

Renaud, Stéphane, M. Chartier, Anne-Françoise Gaudin, et al.. (2025). Epidemiology, patient management, and survival outcomes in resected patients with non-metastatic non-small cell lung cancer: a nationwide real-world study. BMC Cancer. 25(1). 966–966. 2 indexed citations

Comont, Thibault, et al.. (2024). SA67 Health Care Resource Utilization and Associated Costs Among Lower-Risk Myelodysplastic Syndrome Patients in France: Edelweiss Study. Value in Health. 27(12). S627–S627. 1 indexed citations

Rouprêt, Morgan, M. Chartier, Anne-Françoise Gaudin, et al.. (2023). Population characteristics, management, and survival outcomes in muscle-invasive urothelial carcinoma undergoing radical resection: the MINOTAUR study. World Journal of Urology. 41(4). 1069–1075. 4 indexed citations

Alten, Rieke, Hans‐Peter Tony, Bettina Bannert, et al.. (2023). Subcutaneous abatacept for the treatment of rheumatoid arthritis in routine clinical practice in Germany, Austria, and Switzerland: 2-year retention and efficacy by treatment line and serostatus. Clinical Rheumatology. 42(9). 2321–2334. 1 indexed citations

Alten, Rieke, Xavier Mariette, René‐Marc Flipo, et al.. (2022). Retention of subcutaneous abatacept for the treatment of rheumatoid arthritis: real-world results from the ASCORE study: an international 2-year observational study. Clinical Rheumatology. 41(8). 2361–2373. 14 indexed citations

Alten, Rieke, Xavier Mariette, René‐Marc Flipo, et al.. (2021). OP0180 IMPACT OF RF AND ANTI-CITRULLINATED PROTEIN ANTIBODY SEROSTATUS ON 2-YEAR RETENTION OF ABATACEPT IN PATIENTS WITH RA. Annals of the Rheumatic Diseases. 80. 108–108.

Westhovens, René, Seán Connolly, Yedid Elbez, et al.. (2020). Up to 5-year retention of abatacept in Belgian patients with moderate-to-severe rheumatoid arthritis: a sub-analysis of the international, observational ACTION study. Rheumatology International. 40(9). 1409–1421. 5 indexed citations

10.

Chartier, M., et al.. (2019). Malnutrition with hypoaminoacidemia in a 22-year-old pregnant patient masking a likely ornithine transcarbamylase deficiency. Clinical Nutrition ESPEN. 30. 89–93. 2 indexed citations

11.

Alten, Rieke, Eugen Feist, Hanns‐Martin Lorenz, et al.. (2019). Abatacept retention and clinical outcomes in rheumatoid arthritis: real-world data from the German cohort of the ACTION study and a comparison with other participating countries. Clinical Rheumatology. 38(11). 3049–3059. 5 indexed citations

12.

Peichl, P., Rieke Alten, Mauro Galeazzi, et al.. (2019). Abatacept retention and clinical outcomes in Austrian patients with rheumatoid arthritis: real-world data from the 2-year ACTION study. Wiener Medizinische Wochenschrift. 170(5-6). 132–140. 6 indexed citations

13.

Alten, Rieke, Xavier Mariette, Hanns‐Martin Lorenz, et al.. (2019). Predictors of abatacept retention over 2 years in patients with rheumatoid arthritis: results from the real-world ACTION study. Clinical Rheumatology. 38(5). 1413–1424. 27 indexed citations

14.

Mariette, Xavier, Thierry Schaeverbeke, Philippe Gaudin, et al.. (2019). Two-year abatacept retention rate in clinical practice in the French ACTION cohort. Joint Bone Spine. 86(6). 753–759. 7 indexed citations

15.

Mariette, Xavier, Rieke Alten, H. Nüßlein, et al.. (2016). The effect of body mass index on clinical response to abatacept as a first-line biologic for rheumatoid arthritis: 6-month results from the 2-year, observational, prospective ACTION study. Joint Bone Spine. 84(5). 571–576. 16 indexed citations

16.

Nüßlein, H., Rieke Alten, Mauro Galeazzi, et al.. (2015). Prognostic factors for abatacept retention in patients who received at least one prior biologic agent: an interim analysis from the observational, prospective ACTION study. BMC Musculoskeletal Disorders. 16(1). 176–176. 34 indexed citations

17.

Nüßlein, H., Rieke Alten, Mauro Galeazzi, et al.. (2014). Real-world effectiveness of abatacept for rheumatoid arthritis treatment in European and Canadian populations: a 6-month interim analysis of the 2-year, observational, prospective ACTION study. BMC Musculoskeletal Disorders. 15(1). 14–14. 41 indexed citations

18.

Saraux, Alain, et al.. (2010). Survey of the therapeutic management of rheumatoid arthritis in France: the OPALE study.. PubMed. 28(3). 325–32. 3 indexed citations

19.

Oriol, P., et al.. (2009). Allo-immunisation anti-RH1 (anti-D) après transfusion de concentrés plaquettaires issus de donneurs RH :1. Annales de biologie clinique. 67(3). 353–357. 3 indexed citations

20.

Fabrigli, P., et al.. (2007). Évaluation d’un enseignement en transfusion sanguine proposé aux professionnels des établissements de santé. Transfusion Clinique et Biologique. 14(4). 420–432. 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact